Lin Mengmeng, Xiong Weiping, Wang Shiyuan, Li Yingying, Hou Chunying, Li Chunyu, Li Guohui
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Cardiology, Shanghai Putuo District Liqun Hospital, Shanghai, China.
Front Cardiovasc Med. 2022 Jan 12;8:821663. doi: 10.3389/fcvm.2021.821663. eCollection 2021.
In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal antibody against HER-2. The most significant adverse effect of trastuzumab is cardiotoxicity, which has become an important factor in limiting the safe use of the drug. Unfortunately, the mechanism causing this cardiotoxicity is still not completely understood, and the use of preventive interventions remains controversial. This article focuses on trastuzumab-induced cardiotoxicity, reviewing the clinical application, potential cardiotoxicity, mechanism and discussing the potential interventions through summarizing related researches over the past tens of years.
近年来，乳腺癌的发病率逐年上升。人表皮生长因子受体2（HER-2）在15%-20%的人类乳腺癌中过度表达，这与预后不良和高复发率相关。曲妥珠单抗是首个针对HER-2的人源化单克隆抗体。曲妥珠单抗最显著的不良反应是心脏毒性，这已成为限制该药物安全使用的重要因素。遗憾的是，导致这种心脏毒性的机制仍未完全明确，预防性干预措施的应用仍存在争议。本文聚焦于曲妥珠单抗所致心脏毒性，通过总结过去几十年的相关研究，对其临床应用、潜在心脏毒性、机制进行综述，并探讨潜在的干预措施。
